エピソード

  • Glaukos' MIGS Technology Certified in Europe; New Phase 3 Data for Presbyopia Drop

    Glaukos' MIGS Technology Certified in Europe; New Phase 3 Data for Presbyopia Drop
    2025/07/02
    Glaukos receives European Union certification for several of its MIGS technologies; Opus Genetics and Viatris present phase 3 results for their investigational presbyopia eye drop; and J&J launches the first and only daily disposable contact lens for people with both astigmatism and presbyopia. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    5 分
  • Special Report: Update on Holland Foundation

    Special Report: Update on Holland Foundation
    2025/06/25
    The leaders of the Holland Foundation provide an update on the progress of the foundation and its mission to restore sight for patients with Severe Ocular Surface Disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    9 分
  • TFOS DEWS III Published

    TFOS DEWS III Published
    2025/06/18
    The Tear Film and Ocular Surface Society publishes the third installment of the TFOS DEWS report; J&J launches the Tecnis Odyssey presbyopia-correcting IOL in Europe, the Middle East, and Canada; and Harrow acquires the exclusive US commercial rights to postoperative inflammation and pain drug Byqlovi. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    5 分
  • First Myopia Drug Approved in Europe

    First Myopia Drug Approved in Europe
    2025/06/11
    The first pharmaceutical treatment for myopia is approved in Europe; the FDA sets a target action date for a first-of-its-kind presbyopia drop; and John Berdahl, MD, discusses the reimbursement landscape in ophthalmology. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    5 分
  • Alcon Gains FDA Approval for Novel DED Drug

    Alcon Gains FDA Approval for Novel DED Drug
    2025/06/04
    Alcon receives FDA approval for a novel pharmaceutical treatment for dry eye disease; Genentech’s Susvimo ocular implant is approval for a third indication in the US; and the makers of two investigational treatments for wet AMD complete enrollment in their respective phase 3 trials. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    8 分
  • Special Report: Executives Discuss Overcoming Challenges

    Special Report: Executives Discuss Overcoming Challenges
    2025/05/28
    Ophthalmology executives share challenging situations they encountered, as well as the steps needed to overcome the challenge. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    22 分
  • B+L Launches New Scleral Lenses Technology

    B+L Launches New Scleral Lenses Technology
    2025/05/21
    B+L launches a new scleral lenses technology in the US; New World Medical introduces a transparent tip on its Streamline Surgical System, and an OCT platform is cleared in Europe. Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    4 分
  • B+L Receives Approval in Europe for LuxLife IOL

    B+L Receives Approval in Europe for LuxLife IOL
    2025/05/14
    Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions Learn more about your ad choices. Visit megaphone.fm/adchoices
    続きを読む 一部表示
    6 分